ReviewJournal of atherosclerosis and thrombosis2017
Postprandial Hyperlipidemia and Remnant Lipoproteins.
Review in Journal of atherosclerosis and thrombosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 144 citations in OpenAlex.
- Acute Antiplatelet Effects of an Oleocanthal-Rich Olive Oil in Type II Diabetic Patients: A Postprandial Study.International journal of molecular sciences · 2024Trial
- Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.Journal of atherosclerosis and thrombosis · 2023Trial
- Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.Journal of atherosclerosis and thrombosis · 2020Trial
- A comprehensive metabolic profiling of the metabolically healthy obesity phenotype.Lipids in health and disease · 2020Trial
- Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia.Advances in therapy · 2020Trial
- Effects of a diet naturally rich in polyphenols on lipid composition of postprandial lipoproteins in high cardiometabolic risk individuals: an ancillary analysis of a randomized controlled trial.European journal of clinical nutrition · 2020Trial
- Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: A randomized cross-over pilot study.Journal of diabetes investigation · 2019Trial
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.Journal of atherosclerosis and thrombosis · 2018Trial
- Article
- Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circulation research · 2026Review
- An Elevated Serum Apolipoprotein C-III Concentration is Associated with the Risk of Coronary Heart Disease in a Japanese General Population. The Hidaka Cohort Study.Journal of atherosclerosis and thrombosis · 2026Article
- Mediating role of lipid metabolism on the association between egg consumption and frailty: results from a large-scale population study.European journal of nutrition · 2026Article
- Does Pemafibrate Lower Low-Density Lipoprotein-Cholesterol?Journal of atherosclerosis and thrombosis · 2025Article
- Apolipoprotein B48 as a Marker of Residual Coronary Risk: Diagnostic Insights from a Comparative Analysis with Ankle-Brachial Index.The Kobe journal of medical sciences · 2025Article
- Article
- Time-Restricted Eating, ANGPTL4, and Reduction in Residual Cardiovascular Risk.Journal of clinical medicine · 2025Article
- Omega-3 Fatty Acids and Exercise in Obesity Management: Independent and Synergistic Benefits in Metabolism and Knowledge Gaps.Biology · 2025Review
- The Clinical Implication of Pemafibrate, a Novel Selective PPARα Modulator.Journal of atherosclerosis and thrombosis · 2025Article
- Proteomic Analysis of Human Chylomicron Remnants Isolated by Apolipoprotein B-48 Immunoprecipitation.Journal of atherosclerosis and thrombosis · 2025Article
- Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis.Journal of lipid and atherosclerosis · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fasting hypertriglyceridemia is positively associated with the morbidity of coronary heart disease (CHD), and postprandial (non-fasting) hypertriglyceridemia is also correlated with the risk status for CHD, which is related to the increase in chylomicron (CM) remnant lipoproteins produced from the intestine. CM remnant particles, as well as oxidized low density lipoprotein (LDL) or very low density lipoprotein (VLDL) remnants, are highly atherogenic and act by enhancing systemic inflammation, platelet activation, coagulation, thrombus formation, and macrophage foam cell formation. The cholesterol levels of remnant lipoproteins significantly correlate with small, dense LDL; impaired glucose tolerance (IGT) and CHD prevalence. We have developed an assay of apolipoprotein (apo)B-48 levels to evaluate the accumulation of CM remnants. Fasting apoB-48 levels correlate with the morbidity of postprandial hypertriglyceridemia, obesity, type III hyperlipoproteinemia, the metabolic syndrome, hypothyroidism, chronic kidney disease, and IGT. Fasting apoB-48 levels also correlate with carotid intima-media thickening and CHD prevalence, and a high apoB-48 level is a significant predictor of CHD risk, independent of the fasting TG level. Diet interventions, such as dietary fibers, polyphenols, medium-chain fatty acids, diacylglycerol, and long-chain n-3 polyunsaturated fatty acids (PUFA), ameliorate postprandial hypertriglyceridemia, moreover, drugs for dyslipidemia (n-3 PUFA, statins, fibrates or ezetimibe) and diabetes concerning incretins (dipeptidyl-peptidase IV inhibitor or glucagon like peptide-1 analogue) may improve postprandial hypertriglyceridemia. Since the accumulation of CM remnants correlates to impaired lipid and glucose metabolism and atherosclerotic cardiovascular events, further studies are required to investigate the characteristics, physiological activities, and functions of CM remnants for the development of new interventions to reduce atherogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.